Paula Green Sells 3,310 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 3,310 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now owns 84,585 shares in the company, valued at $3,654,917.85. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.
• On Monday, August 5th, Paula Green sold 1,137 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total value of $45,400.41.

Twist Bioscience Trading Up 1.3 %

Shares of NASDAQ TWST opened at $43.34 on Friday. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The firm’s 50-day moving average price is $44.94 and its 200-day moving average price is $43.69. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the prior year, the business earned ($1.01) earnings per share. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC raised its position in Twist Bioscience by 407.1% in the 3rd quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock worth $495,000 after purchasing an additional 8,797 shares during the period. Capital Impact Advisors LLC raised its holdings in shares of Twist Bioscience by 16.1% in the second quarter. Capital Impact Advisors LLC now owns 20,380 shares of the company’s stock worth $1,004,000 after buying an additional 2,821 shares during the period. Algert Global LLC lifted its stake in shares of Twist Bioscience by 114.8% during the 2nd quarter. Algert Global LLC now owns 27,300 shares of the company’s stock worth $1,345,000 after acquiring an additional 14,590 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in Twist Bioscience by 63.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after acquiring an additional 150,260 shares during the period. Finally, Scientech Research LLC increased its stake in Twist Bioscience by 102.7% in the second quarter. Scientech Research LLC now owns 31,435 shares of the company’s stock worth $1,549,000 after purchasing an additional 15,924 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TWST shares. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. TD Cowen lifted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Barclays reduced their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.63.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.